Advances in glaucoma diagnosis and therapy for the next millennium: new drugs for trabecular and uveoscleral outflow.
Advances in our understanding of the physiology and molecular biology of the trabecular and uveoscleral outflow pathways of the eye will lead to the development of new approaches for glaucoma therapy. Therapies of the future will target the structures and enzymes involved in maintaining cell shape and cell-cell and cell-extracellular matrix interactions. Altering the extracellular matrix in the ciliary muscle has been important in the intraocular pressure lowering effects of prostaglandins and will be developed further as an approach to enhancing outflow through the trabecular meshwork. Gene therapy may be used to enhance or suppress the endogenous targets that are ultimately responsible for the outflow enhancement triggered by these agents.
Kaufman
P L
PL
Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI 53792-3220, USA.
Gabelt
B
B
Tian
B
B
Liu
X
X
D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001082:Aqueous Humor / Q000378:metabolism*; D002924:Ciliary Body / Q000187:drug effects* / Q000378:metabolism; D005901:Glaucoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects / Q000502:physiology; D012590:Sclera / Q000187:drug effects* / Q000378:metabolism; D014129:Trabecular Meshwork / Q000187:drug effects* / Q000378:metabolism
D000959:Antihypertensive Agents